Ignite Creation Date:
2025-12-26 @ 10:56 AM
Ignite Modification Date:
2025-12-31 @ 9:08 PM
Study NCT ID:
NCT01009008
Status:
COMPLETED
Last Update Posted:
2018-08-10
First Post:
2009-11-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Patient Activated Controlled Expansion (PACE) Trial
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001943', 'term': 'Breast Neoplasms'}, {'id': 'D009369', 'term': 'Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 40}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2009-06'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2018-08', 'completionDateStruct': {'date': '2013-06', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-08-08', 'studyFirstSubmitDate': '2009-11-05', 'studyFirstSubmitQcDate': '2009-11-05', 'lastUpdatePostDateStruct': {'date': '2018-08-10', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2009-11-06', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2013-05', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Expansion to and maintenance of clinically desired breast volume (not exceeding implant maximum) until permanent implant placement or 6 months (whichever comes first) unless prohibited by a non-device related failure.', 'timeFrame': '6 months'}], 'secondaryOutcomes': [{'measure': 'Safety as evidenced by a low incidence of device-related adverse events.', 'timeFrame': '6 months'}, {'measure': 'Time required to achieve desired expansion results.', 'timeFrame': '6 months'}, {'measure': 'Overall patient treatment satisfaction.', 'timeFrame': '6 months'}, {'measure': 'Overall surgeon treatment satisfaction.', 'timeFrame': '6 months'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['cancer', 'breast cancer', 'mastectomy', 'breast reconstruction', 'reconstruction', 'tissue expansion', 'two-stage breast reconstruction', 'tissue expander', 'AeroForm', 'AirXpander'], 'conditions': ['Breast Cancer', 'Mastectomy', 'Breast Reconstruction']}, 'referencesModule': {'references': [{'pmid': '25357043', 'type': 'DERIVED', 'citation': 'Connell TF. Patient-activated controlled expansion for breast reconstruction using controlled carbon dioxide inflation: confirmation of a feasibility study. Plast Reconstr Surg. 2014 Oct;134(4):503e-511e. doi: 10.1097/PRS.0000000000000551.'}, {'pmid': '21921761', 'type': 'DERIVED', 'citation': 'Connell AF. Patient-activated controlled expansion for breast reconstruction with controlled carbon dioxide inflation: a feasibility study. Plast Reconstr Surg. 2011 Oct;128(4):848-852. doi: 10.1097/PRS.0b013e3182268b80.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to determine whether a patient controlled tissue expander can improve the results and patient experience in breast reconstruction. The study hypothesis is that patient controlled expansion will lead to rapid and more comfortable outcomes than historical precedents.', 'detailedDescription': 'Title: Patient Activated Controlled Expansion (PACE) for Breast Reconstruction Utilizing Controlled CO2 Inflation\n\nDesign: Prospective, open-label, single-arm, feasibility trial Purpose: To evaluate the AirXpanders tissue expander in patients undergoing breast reconstruction surgery following mastectomy.\n\nEnrollment: This feasibility trial will enroll up to 10 patients. Following enrollment of the first 5 patients, the sponsor will determine if additional subjects will be recruited to further evaluate treatment outcome.\n\nClinical Sites: Up to 3 sites and 3 surgeons will participate in this study. The surgeon(s) should have the necessary qualifications and sufficient experience (minimum of 12 breast tissue expanders placed per year) to participate in the trial.\n\nDuration of Patient Participation: Eligible patients will be enrolled over approximately 2 months.\n\nPatients will be instructed on the tissue expansion protocol pre-operatively and undergo post-operative clinical follow-up on a weekly basis or more frequently if deemed necessary by the treating surgeon.\n\nEach patient will be followed through removal of the tissue expander.\n\nStudy Population:\n\nThe study population will consist of up to 10 patients. Eligible patients are females between the ages of 18 and 65 years who are planning to undergo breast reconstruction surgery following mastectomy. Eligible patients must be able to provide informed consent and understand protocol components.'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Female between the ages of 18 and 65 years.\n2. Planned breast reconstruction surgery post-mastectomy.\n3. Able to provide informed consent.\n4. Able to understand protocol components.\n\nExclusion Criteria:\n\n1. Tissue at the intended expansion site is determined unsuitable by the surgeon (i.e., infection, compromised vascularity, history of compromised wound healing, mastectomy skin flaps of questionable viability, excessively tight skin envelope, previous radiation treatment, active ulceration)\n2. Residual gross tumor at the intended expansion site\n3. History of or planned adjuvant radiation therapy\n4. Co-morbid condition determined by the surgeon to pose unduly high risk of surgical and/or postoperative complications.\n5. Obesity with BMI of 30 or above\n6. Current smoker\n7. Psychologically unsuitable patient\n8. Patient unable to understand the protocol for tissue expansion\n9. Planned flight or assent to altitude exceeding 1000 meters above baseline during the expansion period.'}, 'identificationModule': {'nctId': 'NCT01009008', 'acronym': 'PACE', 'briefTitle': 'Patient Activated Controlled Expansion (PACE) Trial', 'organization': {'class': 'INDUSTRY', 'fullName': 'AirXpanders, Inc.'}, 'officialTitle': 'Patient Activated Controlled Expansion (PACE) for Breast Reconstruction Utilizing Controlled CO2 Inflation', 'orgStudyIdInfo': {'id': 'CTP-0001'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Post-mastectomy', 'description': 'Post-mastectomy patients undergoing expander reconstruction', 'interventionNames': ['Device: Patient Activated Controlled Expansion Device']}], 'interventions': [{'name': 'Patient Activated Controlled Expansion Device', 'type': 'DEVICE', 'description': 'Patient activated controlled expansion for post-mastectomy breast reconstruction', 'armGroupLabels': ['Post-mastectomy']}]}, 'contactsLocationsModule': {'locations': [{'zip': '6000', 'city': 'Perth', 'state': 'Western Australia', 'country': 'Australia', 'facility': 'The Mount Hospital', 'geoPoint': {'lat': -31.95224, 'lon': 115.8614}}], 'overallOfficials': [{'name': 'Anthony Connell, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'AirXpanders, Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}